Patents by Inventor Allen Ka Loon Cheung

Allen Ka Loon Cheung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against novel PD1 isoforms and uses thereof
    Patent number: 11236144
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 1, 2022
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • Antibodies Against Novel PD1 Isoforms and Uses Thereof
    Publication number: 20180312564
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 1, 2018
    Inventors: ZHIWEI CHEN, LIN CHENG, ALLEN KA LOON CHEUNG, JINGYING ZHOU
  • Antibodies against novel PD1 isoforms and uses thereof
    Patent number: 10047137
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: August 14, 2018
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • NOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSES
    Publication number: 20140302070
    Abstract: In one embodiment, the present invention provides a new isoform of human PD1 (?42PD1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. ?42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines In one embodiment, ?42PD1 can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8+ T cell immunity and for prevention of pathogenic infection and/or cancer. In one embodiment, soluble ?42PD1 protein could be a therapeutic target for autoimmune diseases. In other embodiments, proteins or peptides or nucleic acids encoding proteins or peptides containing ?42PD1 could be used as immunogens for developing antibodies binding specifically to ?42PD1. In yet another embodiment, neutralizing antibodies could block s?42PD1 function and accordingly could be used as treatment for autoimmune disorders.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 9, 2014
    Applicant: The University of Hong Kong
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou